Research output per year
Research output per year
Personal profile
specialisation
oncolytic immunotherapy, therapeutic target discovery, high-throughput functional genomic screening, cancer therapy development
-
Research interests
The ultimate goal of the applied research in my laboratory is to make new, more effective medicines available for treatment of cancer patients. Towards this goal, two main strategies are followed.
Therapeutic target discovery: We perform high-throughput functional genomic screens with RNAi libraries to identify vulnerabilities in cancer cells. Next, we use validated leads from completed screens to discover new anticancer drugs and to design new treatment strategies.
Oncolytic immunotherapy: We apply molecular knowledge of cancer and viruses to develop next-generation oncolytic adenoviruses for personalized therapeutic vaccination. These viruses replicate in and kill cancer cells selectively, thereby inducing an adaptive immune response against released tumor antigens. We focus on promoting lytic replication and counteracting immune suppression in the tumor microenvironment.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD, Gene Therapy for Adenosine Deaminase Deficiency: Preclinical Studies, Leiden University, Leiden, Netherlands
Award Date: 16 Sept 1993
External positions
President, Netherlands Society of Gene and Cell Therapy
15 Mar 2018 → 31 Dec 2099
Chief Scientific Officer, ORCA Therapeutics
1 May 2008 → 31 Dec 2099
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Expression of Oncolytic Adenovirus-Encoded RNAi Molecules Is Most Effective in a pri-miRNA Precursor Format
Brachtlová, T., van Ginkel, J-W., Luinenburg, MJ., de Menezes, R. X., Koppers-Lalic, D., Pegtel, DM., Dong, W., de Gruijl, TD. & van Beusechem, VW., 16 Dec 2020, In: Mol Ther Oncolytics. 19, p. 332-343 12 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access8 Citations (Scopus) -
High-throughput RNAi screening reveals cancer-selective lethal targets in the RNA spliceosome
Blijlevens, M., van der Meulen-Muileman, I. H., de Menezes, R. X., Smit, E. F. & van Beusechem, V. W., 23 May 2019, In: Oncogene. 38, 21, p. 4142-4153 12 p.Research output: Contribution to journal › Article › Academic › peer-review
13 Citations (Scopus) -
Functional Screening Identifies Human miRNAs that Modulate Adenovirus Propagation in Prostate Cancer Cells
Hodzic, J., Sie, D., Vermeulen, A. & Van Beusechem, V. W., 1 Sept 2017, In: Human gene therapy. 28, 9, p. 766-780 15 p.Research output: Contribution to journal › Article › Academic › peer-review
20 Citations (Scopus) -
A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment
Siebring-van Olst, E., Blijlevens, M., de Menezes, R. X., van der Meulen-Muileman, I. H., Smit, E. F. & van Beusechem, V. W., May 2017, In: Molecular Oncology. 11, 5, p. 534-551Research output: Contribution to journal › Article › Academic › peer-review
46 Citations (Scopus) -
ORCA-010, a Novel Potency-Enhanced Oncolytic Adenovirus, Exerts Strong Antitumor Activity in Preclinical Models
Dong, W. L., van Ginkel, J. W. H., Au, K. Y., Alemany, R., Meulenberg, J. J. M. & van Beusechem, V. W., 2014, In: Human gene therapy. 25, 10, p. 897-904Research output: Contribution to journal › Article › Academic › peer-review
23 Citations (Scopus)
Prizes
-
Netherlands Society of Gene Therapy Greiner Award 2000
van Beusechem, Victor (Recipient), 23 Mar 2001
Prize › Academic
-
Royal Netherlands Academy of Arts and Sciences Fellowship
van Beusechem, Victor (Recipient), 2000
Prize › Academic